IRadimed Co. (NASDAQ:IRMD) CEO Sells $403,100.00 in Stock

IRadimed Co. (NASDAQ:IRMD) CEO Roger E. Susi sold 10,000 shares of IRadimed stock in a transaction on Tuesday, November 23rd. The stock was sold at an average price of $40.31, for a total transaction of $403,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

IRMD stock opened at $43.00 on Thursday. IRadimed Co. has a 1-year low of $21.65 and a 1-year high of $45.01. The firm has a fifty day moving average price of $36.45 and a two-hundred day moving average price of $33.38. The firm has a market cap of $530.71 million, a price-to-earnings ratio of 89.58 and a beta of 0.90.

IRadimed (NASDAQ:IRMD) last released its earnings results on Thursday, October 28th. The medical equipment provider reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.06. IRadimed had a net margin of 15.77% and a return on equity of 9.44%. During the same quarter last year, the business earned $0.09 earnings per share. As a group, equities research analysts predict that IRadimed Co. will post 0.62 earnings per share for the current fiscal year.

A number of analysts recently issued reports on IRMD shares. Zacks Investment Research upgraded shares of IRadimed from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Thursday, November 4th. Roth Capital lifted their price target on shares of IRadimed from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, November 2nd. Finally, TheStreet upgraded shares of IRadimed from a “c+” rating to a “b” rating in a research note on Friday, July 30th.

A number of hedge funds have recently added to or reduced their stakes in IRMD. Vanguard Group Inc. grew its position in shares of IRadimed by 62.2% during the second quarter. Vanguard Group Inc. now owns 489,913 shares of the medical equipment provider’s stock worth $14,408,000 after acquiring an additional 187,953 shares during the last quarter. BlackRock Inc. grew its position in shares of IRadimed by 2.9% during the third quarter. BlackRock Inc. now owns 416,845 shares of the medical equipment provider’s stock worth $14,002,000 after acquiring an additional 11,833 shares during the last quarter. Geode Capital Management LLC grew its position in shares of IRadimed by 5.4% during the third quarter. Geode Capital Management LLC now owns 101,659 shares of the medical equipment provider’s stock worth $3,414,000 after acquiring an additional 5,176 shares during the last quarter. State Street Corp grew its position in shares of IRadimed by 5.5% during the second quarter. State Street Corp now owns 96,438 shares of the medical equipment provider’s stock worth $2,836,000 after acquiring an additional 4,993 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of IRadimed by 33.9% during the third quarter. Dimensional Fund Advisors LP now owns 87,684 shares of the medical equipment provider’s stock worth $2,946,000 after acquiring an additional 22,190 shares during the last quarter. Hedge funds and other institutional investors own 39.18% of the company’s stock.

IRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Featured Article: CD Ladder

Insider Buying and Selling by Quarter for IRadimed (NASDAQ:IRMD)

Receive News & Ratings for IRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRadimed and related companies with MarketBeat.com's FREE daily email newsletter.